Back to Journals » OncoTargets and Therapy » Volume 10

Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer

Authors Roviello G, Corona SP, Bonetta A, Cappelletti MR, Generali D

Received 1 June 2017

Accepted for publication 30 June 2017

Published 31 July 2017 Volume 2017:10 Pages 3811—3815

DOI https://doi.org/10.2147/OTT.S143020

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Ingrid Espinoza

Giandomenico Roviello,1,2 Silvia Paola Corona,3 Alberto Bonetta,4 Maria Rosa Cappelletti,5 Daniele Generali2,5

1Medical Oncology Unit, Department of Oncology, San Donato Hospital, Arezzo, 2Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy; 3Radiation Oncology Department, Peter MacCallum Cancer Centre, Moorabbin Campus, East Bentleigh, VIC, Australia; 4Radiotherapy Department, 5Breast Cancer Unit, Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy

Abstract: The aim of this study was to evaluate the correlation between circulating tumor cells (CTCs) and patterns of recurrence in patients with hormone-sensitive prostate cancer. The study involved patients with histologically confirmed, advanced prostatic adenocarcinoma, who were tested for CTCs (Veridex®) when they developed recurrence after radical prostatectomy or external beam radiation between 2008 and 2014. Forty-two prostate cancer patients were evaluated. CTCs were detected in 14 out of 42 (33.3%) patients (Group A), while the remaining 28 (66.7%) showed undetectable levels of CTCs (Group B). The mean prostate-specific antigen value was higher in Group A in comparison to Group B (6.2 vs 3.3 ng/dL) (P=0.48). Presence of bone metastases alone or along with nodal metastases was more common in Group A (57.1%) in comparison to Group B (25%) (P=0.04). In a univariate analysis, the presence of CTCs at diagnosis correlated with the development of bone recurrence (OR: 4; 95% CI: 1.0–15.9; P=0.05). Even if the study enrolled only a small number of patients, the detection of CTCs in the blood appears to correlate with the pattern of progression in patients with hormone-sensitive prostate cancer, suggesting a possible role in anticipating recurrence at the bone in men with higher tumor load. Further prospective studies are warranted in this setting.

Keywords: prostate cancer, CTCs, bone metastasis, biochemical failure

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

The distinctive nature of adenocarcinoma of the lung

Roviello G

OncoTargets and Therapy 2015, 8:2399-2406

Published Date: 2 September 2015